S. 2292 · 119th Congress · Health
Over-the-Counter Monograph Drug User Fee Amendments
- IntroducedJul 15, 2025 Done
- CommitteeReported Sep 8, 2025 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA); revises procedures used by the Food and Drug Administration (FDA) to evaluate topical, nonprescription drugs (e.g., sunscreens); and requires the FDA to clarify the process through which a prescription drug may be switched to nonprescription status.
Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the FDA, rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective. The bill reauthorizes the collection of OMUFA fees from OTC drug facilities through FY2030 and revises methods for calculating such fees.
Separately, the bill requires the FDA to allow for the use of real-world evidence to demonstrate the safety and effectiveness of active ingredients in topical, nonprescription drugs. The FDA must consider nonclinical tests and other alternatives to animal testing in evaluating such drugs.
The FDA must also issue guidance to clarify the application process for nonprescription drugs, including applications to switch a prescription drug to nonprescription status. The FDA must plan to engage stakeholders in identifying drugs that are promising candidates for a switch. Moreover, applicants seeking a switch may request to meet with the FDA to develop a plan for the requisite application.
Finally, the Government Accountability Office must report on (1) the OTC monograph drug supply chain, and (2) the FDA’s handling of applications to switch a prescription drug to nonprescription status.
Congressional Research Service · summary of “Reported to Senate” version · Sep 8, 2025
Who lobbies on it
5 organizations, more than 92% of Senate bills · 19 filings · Q3 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
American Academy of Dermatology Association
5 of 5 quarters
“H.R. 3686, the SAFE Sunscreen Standards Act; H.R. 4273/S. 2292, Over-the-Counter Monograph Drug User Fee Amendments; H.R. 5509/S. 2903, the Safe Step Act; H.R. 4002, the Patient Access to Higher Quality Health Care Act of 2025 Clinical Laboratory Improvement Amendment”
$3.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Consumer Healthcare Products Association
5 of 5 quarters
“S.2292 - Over-the-Counter Monograph Drug User Fee Amendments H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments S.355 - FDA Modernization Act 3.0 H.R.2821 - FDA Modernization Act 3.0 H.R.3686 - SAFE Sunscreen Standards Act H.R.1 - One Big Beautiful Bill Act H.R.5371 - Continuing Appropriations and…”
Under $5,000 lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Haleon Us Holdings Llc
2 of 5 quarters
“…S.2292 - Over-the-Counter Monograph Drug User Fee Amendments; S.2513 - OTC Monograph Drug User Fee Transparency Act; S.3122 - Better FDA Act of 2025 General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to…”
$910K lobbying spend in 2025, all issuesQ4 2025 filing
2 more organizations, every filingPROUpgrade
Organizations that named S. 2292 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
5 actions · newest first- Sep 8, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.
- Sep 8, 2025Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jul 30, 2025Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Jul 15, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Show all 5 actionsShow fewer
- Jul 15, 2025Introduced in Senate